Biocure Technology Inc.

Recent News

  • BioCure Technology Inc. Announces Closing of Financing

    Vancouver, British Columbia--(Newsfile Corp. - October 14, 2020) - BioCure Technology Inc. (CSE: CURE) ("BioCure" or the "Company") announces that it will close a non-brokered private placement (the "Private Placement") on October 15th, 2020 consisting of 1,786,725 Units at a price of $0.14 cents per Unit for gross proceeds of $250,142.Each Unit is comprised of one common share (the "Shares) and one share purchase warrant (the "Warrants") of the Company, where each whole Warrant entitles the holder to purchase an...

    2020-10-14 10:53 AM ET
  • BiocurePharm, Korea ("BPK") Signs MOU With S&B Biopharm Enabling Expansion Into The European CAR T Market

    Vancouver, British Columbia--(Newsfile Corp. - September 21, 2020) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a subsidiary of Biocure Technology Inc. ("CURE") is pleased to announce that BPK has entered into a non-binding MOU with S&B Biopharm ("SRB") located in Sofia, Bulgaria. This agreement will allow BPK to locally manufacture CD-19 CAR T in Bulgaria and sell to the Eastern European market, including Poland, Turkey and Bulgaria. Expansion into the European market could...

    2020-09-21 8:15 AM ET
  • BiocurePharm, Korea ("BPK") Provides Corporate Update

    Vancouver, British Columbia--(Newsfile Corp. - September 10, 2020) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF)  ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a subsidiary of Biocure Technology Inc. ("CURE") is pleased to announce that they have been actively pursuing Joint Venture opportunities with several overseas companies including a strategic alliance with the University of Malaya Hospital to move forward with a compassionate human clinical trial (CT) before the end of 2020.BPK is fully ready to implement a clinical trial in...

    2020-09-10 8:15 AM ET
  • BiocurePharm, Korea ("BPK") Announces Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - March 16, 2020) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a subsidiary of Biocure Technology Inc. ("CURE") is pleased to announce that it has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea ("BPK"), BPK has issued 5,990 shares at 12.639 CAD per share for gross proceeds of $75,707. All dollar values are based on the published Exchange Rate of CAD0.001149/KRW1 on March...

    2020-03-16 8:00 AM ET
  • BiocurePharm, Korea ("BPK") Announces Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - January 20, 2020) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a subsidiary of Biocure Technology Inc. ("CURE") is pleased to announce that it has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea ("BPK"), BPK has issued 53,567 shares at 12.375 CAD per share for gross proceeds of $662,892. All dollar values are based on the published Exchange Rate of CAD0.001125/KRW1 on January 17,...

    2020-01-20 9:00 AM ET
  • BiocurePharm, Korea ("BPK") Announces Closing of Convertible Debenture Financing

    Vancouver, British Columbia--(Newsfile Corp. - December 5, 2019) - BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") is pleased to announce that it has closed its Convertible Debenture financing. BPK has issued convertible debentures for gross proceeds of Korean Won660,000,000 (CAD732,600). Its maturity date is December 5, 2029 with the coupon rate of 3%. The investor has a right to convert to common shares of BPK at CAD12.21...

    2019-12-05 9:00 AM ET
  • Biocure Enters into a Clinical Trial for CAR T -Cell Products in Korea

    Vancouver, British Columbia--(Newsfile Corp. - October 17, 2019) - Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (the "Company" or "Biocure") is pleased to announce that Biocure Pharm Corp.("BPK"), a subsidiary of the Company has appointed CLIPS (Clinical Professional Services) as the CRO (Contract Research Organization) to proceed with a Clinical Trial for CAR-T products in Korea. After reviewing multiple competent CRO's in Korea and multiple meetings with them, BPK has selected CLIPS who has outstanding experience as...

    2019-10-17 8:00 AM ET
  • CORRECTION FROM SOURCE: BiocurePharm, Korea ("BPK") Announces Closing of Convertible Debenture Financing

    Vancouver, British Columbia--(Newsfile Corp. - September 19, 2019) - Biocure Technology Corp. (CSE:CURE) (OTCQB: BICTF) ("CURE" or the "Company") wishes to correct its earlier press release of today's date to advise that it has closed its Convertible Debenture financing through its Korean Subsidiary BiocurePharm, Korea ("BPK"), BPK has issued convertible debentures for gross proceeds of Korean Won440,000,000 (CAD490,160). As previously advised, their maturity date is September 9, 2029 with the coupon rate of 3% and the investor has a...

    2019-09-19 8:37 PM ET